The research introduces mechanotherapy, therapies designed to disrupt the mechanical signals that tumors rely on to grow and spread.

By targeting PIEZO1–Rho–ROCK, the study aims to identify patients at risk of aggressive breast cancers and slow tumor progression early on.

The study is published with DOI 10.1126/sciadv.aeb1271.

The work was co-funded by The Hospital Research Foundation Group, Australian Breast Cancer Research, Worldwide Cancer Research, and the Australian Federal Government.

A new Science Advances study identifies the PIEZO1–Rho–ROCK axis as a promising target for early intervention and the development of mechanotherapy to limit breast cancer growth and invasiveness.

Brief mechanical compression of cancer tissue markedly increases tumor growth and pushes cells toward epithelial–mesenchymal transition, enhancing invasiveness.

Breast cancer cells sense pressure through PIEZO1, triggering calcium influx and activating the Rho–ROCK pathway to boost movement and growth.

Blocking PIEZO1 or the Rho–ROCK pathway with drugs prevents compression-induced aggression, establishing these components as key mediators of the mechanical response.

Researchers report a lasting mechanical memory: brief mechanical pressure induces epigenetic changes in histone marks that sustain aggressive tumor behavior even after the pressure is removed.

This durable memory arises from epigenetic histone modifications, propagating the aggressive phenotype beyond the initial mechanical stimulus.

In summary, short-term mechanical pressure reprograms DNA expression via histone changes, maintaining tumor aggressiveness over time.

PIEZO1 is more abundant in human breast cancers than in normal tissue, and higher PIEZO1 levels correlate with poorer patient survival, signaling clinical relevance.